UBS AG buy 8,825,000 6.7%

eSensor LAUNCHED!!!

FDA clearance for Cystic Fibrosis DNA Test

Sales of the eSensor instrument and CF test will commence in the first half of 2006 as planned.. . James White, CEO of Osmetech said: 'Gaining FDA clearance for our first microarray based test developed for our new eSensorTM molecular diagnostics instrument is a major step forward for our Molecular Diagnostics Division and will help to establish Osmetech as a key player in the fast growing moleculardiagnostics market. In addition, this FDA clearance helps to validate our microarray technology for routine use in the laboratory. Critical Care DivisionThe Division has a strong product portfolio and is well placed to continue the growth of instrument placements throughout the world, leading to revenues from proprietary consumables for a number of years to come.Sales of OPTI instruments and consumables remained strong resulting from increased sales of the new touchscreen version of the long-established OPTI (CCA). In 2006 we will start to see an important contribution to sales from the new OPTI LION portable electrolyte analyser and the OPTI R blood gas and electrolyte analyser with reusable consumable as these products are rolled out internationally.' Molecular Diagnostics DivisionFollowing FDA approval of the eSensorTM platform Osmetech are now looking to progress discussions with strategic partners who are looking for cost effective and easy to use instrumentation and consumables to work on other complex assays both in the healthcare and non healthcare markets. The next Osmetech Molecular test targeted for FDA submission will be the CYP 450 pharmacogenomics assay, which is currently in development. James White, CEO of Osmetech commented: 'We have been delighted with the rapid integration of the CMS business acquired in July. The powerful combination of the eSensor product together with OPTI GENE provides Osmetech Molecular Diagnostics with an excellent position in this rapidly developing and growing market sector. Both products remain on schedule for launch and revenue generation in the first half of 2006'

Sales to year end up over 40%

Osmetech has reported a strong rise in sales in the latter part of 2005 with growth driven byabove-forecast revenues at its Critical Care blood gas analysis division.. Sales for the Critical Care division in calendar year 2005 exceeded $14.7m, representing an increase of over 60% compared to the calendar year 2004. Approximately half of this overall growth is due to sales to veterinary distribution partner, IDEXX Laboratories, Inc.

Vetstat Exceeds Idexx Expectations

Sales of the VetStat electrolyte and blood gas analyser have been very encouraging and continue to exceed expectations. IDEXX's sales successes and continuing marketing efforts should result in further strong growth for the foreseeable future. As the installed base of instruments becomes established, revenues from proprietary consumables are expected to increase as a proportion of this veterinary business. Following a deal with leading US vetinary hopsital chain Banfield, Idexx are contracted to supply an additional 450 Vetstat devices over the coming year.Good progress is also being made with IDEXX on the development and supply contract to create a new platform for measuring critical care parameters based on Osmetech's proprietary optical fluorescence technology and consumables. It is anticipated that this market leading product is on target for launch late 2006/2007.

Critical Care Product Range - In Production

OPTI-CCA OPTI-LION OPTI-R OPTI-2L

Critical Care Consumable Product Range - In Production

SamplerCassette Callibration DataTrol

Molecular Diagnostics Product Range - In Production

Opti-GeneeSensorBiochipConsumableOPTI Tube Product Range - Licenced to Third Party

VetStat Cassettes OPTI Tube AVOX 4000

Buisness Partners

Major Shareholders

Organisation Shareholding % Gartmore 24,109,657 18.29% Schroder 18,874,284 14.32 UBS AG 8,825,000 6.70TD Waterhouse 7,011,137 5.32 Barclays Nom 6,638,092 5.04 Pershing Keen 5,870,773 4.45HSBC Global Nom 6,544,718 4.97 Roche 2,444,688 1.8 Marlborough UK Micro Cap Director Holdings James White 208,092 Gordon Hall 104,966 D Sandilands 61,597 GB Kuenster 33,054 A Marek 26,190 ADVFN Posters 5,896,564 4.5 Total Holdings 86,648,812 65.7%

Mouse Over Images For Product Data

If regular posters would like to be included in the ADVFN figure and if you are not bothered about the figures being public then post your long-term holding here.IE the number of shares you intend to keep for say more than 6 months?Alternatively if you'd rather keep your holdings secret but still want contribute to the overall figure then drop me a line to ditchpig@ntlworld.com

WANT TO POST THAT ON III SITE THINK THEY ARE HANGING THE NOOSE!!!!

TIPPED BY CITYWIRE 10.00 PER MONTH SUBS
Osmetech's shares have dropped 0.375p today to 3.3p which looks like a good buying opportunity given the solid base provided by the existing Opti business. The potential of the new products and management's confidence about second half prospects.

However, the shares are very high risk and trade on a fairly wide spread.

The cash position is encouraging though and provides some security. The group finished the half year with 3.6 million after getting 1.5 million in cash from its all paper acquisition of Molecular Sensing after accounting for take over costs. Buy.

it would seem every 1 sees the price falling so follows the sheep and sells.
ER HELLO stop and think why you are selling !! what just because the share price is falling...................................TOP UP CANT YOU ALL SEE.

im following Kitcat not the sheep

mm are putting buys through as sells so the HEARD will get bigger

just sent JW an email wonder if i will get a reply?
and what he has to say!!!!

Depends on if you used a spell check. What did you ask?

You mean your not going to bar me from this site as well!

Change of heart, your out the sin bin!

So what were your questions to JW- When's the share price going to go up lots??

feb last year JW was available for comments on ADVFN said would be nice to be able to do the same and when he planned it as i felt that although im not bothered about the share price there were people who were loosing confidence in OMH and i felt it was his job to keep investors like our self's more updated and if people are able to put views and question accross it would shut some people up from moaning.
he simply replied............
No problem i will put he price up 3% today!!!! NOT im stil waiting for a reply what do you think or you going to slate me?

also pointed out its nice to see a director buying shares

Trouble is matey advfn doesn't do web casts anymore. I agree it would be a good opportunity to boost sentiment and tie up a few un answered questions amongst holders, its a shame they removed that service.

As far as directors buying shares i wouldnt hold your breath they are loaded up with options exercisable over 4p(ish without checking).

What would be nice is to see the 2 new key members of staff buying a small stake to show their confidence in the company & bringing OPTI-gene to the market. Perhaps this wont happen for sometime, until they have a better feel for how things are progressing......but i could be wrong!

No reply from the company yet Aztec0? Seems like your email went straight into the recycle bin..

DOING YOUR HOME WORK I SEE aztec0?
No reply yesterday so i sent it again stating that should a supplier MAIL an order worth a vast amount i should hope he replies a dam site faster than this!!!!!!
STILL WAITING.............MAYBE TRY THE OLD TELEPHONE

12,650,000 is that you MR WHITE in regards to my email!!!!! nice 2 see the MOTHS are flying!!!!

LOL

BANG JUST CALLED OMH
ALL IN A MEETING AND NOT TAKING CALLS 4:45PM THEY ARE CALLING ME BACK

IDEXX now showing VETSTAT on their website. Also being exhibited at a load of conferences and vet type gatherings around the US and UK over the next few months. (see competitors OMH thread for more details and dates etc)

http://www.idexx.com/AnimalHealth/analyzers/vetstat/index.cfm

Extracted from an alternative OMH thread, a recent conversation with DS.

snorky2 - 31 Mar'05 - 18:32 - 4107 of 4124 moderate post | add to banned list


HOPE THIS HELPS:

1. Will there be a trading statement at year-end?

NO we dont do a yearend trading statement but any info or news will be announced
through normal channels.


2. Is development still happening on OPTI IV for ROCHE? Or has the ROCHE OMNI filled that gap?

NO its on the back boiler since buying company but could be used in the future. If
they intend to use it Roch will have the first choice of refusal

3. Are the new OPTI product launches still on track? or has the development of OptiGENE taken precedence?

No. The Optigene has not taken precedence. It is 2 sets of people bringing 2 bits to the market and yes the OPTI products are on track


4. Is IDEXX progressing as well as anticipated?

Yes very happy. It was displayed at the trade show in January and the reaction was
very good way ahead of what they expected it to be and the response on what they
regard as firm leads with people leaving details saying yes they are very
interested and they are in the process of making and shipping the product around
the world.



5. Are IDEXX buying large chunk of machines or are they buying to order for their customers.

They buy in bulk in anticipation of getting buyers to buy from them so no cash flow problems. Because they buy more units they get them at a discount to the health care market and sell them on around the world. He stated that the discounts were agreed because of the amount of units that they were likely to be selling. It is the same product as used in the health care but different software. Different badge but basically the same product. IDEXX have the chance to sell significantly more products to one customer and quoted simple clean business. With IDEXX funding all the advertising and sales staff all omh do is manufacture and sell to them.



6. How are sales progressing across the company compared with quoted expectations in
the reports.
The fall in figures explained in reports: But the sales will still show a significant improvement in the second half.
Sales going well and if sales were not going as planned they would be obliged to inform the market. SO very good.



7. Are their any new uses that the optigene can be used for apart from what has already been mentioned in report?

Very simple and fast for DNA analysis, Test for absence of a certain gene, Diagnose a
Disease, Searching for a foreign DNA, Sexually transmitted diseases: chlymidia,



8. What will the OptiGENE be used for first.

Will be used for the principle use of virginal infections market and make this a
priority and one or 2 more areas to applying the optigene. If there are Thrombosis
markers for genetics and someone is about to go for an operation it is important in
knowing how that persons blood will clot and recovery process after surgery, there
are certain genes associated with thrombosis and it can help with the assessment of
how the patient can recover from that operation.


9. What needs to be done before a test for chlamydia can be
marketed and how soon do you think it will be on the market.

Working with lgc who have a very good chemistry is highly sensitive and works very well with the optigene. Using tests to identify the chlymidia bacteria works very well with the omh device. There were able to demonstrate in tests in London the instrument worked very quickly and accurate in identifying chlymidia. Will be showed in November which is Europes biggest medical show and they will be showing a finished product and with a view to shipping that product in the first half of next year. IT will not be used initially for sexually transmitted diseases that will be probably follow a few months after that. He stressed that it is very simple to use, accurate and very quick. Then went on to stress the importance of diagnosing patients quickly for obvious reasons.




10. When was the last time a MARKET analyst visited the company

One just started in America to follow the company.



11. I think I heard someplace that you did a presentation to some
institutes if how did it go.

Yes impressed and waiting for finished product on the market then they would show further interest in the company. Once the product sells and profits show they will show further interest but explained they dont mind buying at a higher price once the share price is moving. He said he believes they are on course but is yet still to come.


12. Which Company do you think will give omh the most competition and is omh doing to
combat this.

Optigene, there are lots of competition out there but this has the benefit of being very cost effective, the price of the unit and will sell cheaper in bulk buys, simple to use, quick. They are cheaper than all competitors and no one can offer the same benefits of the optigene. He goes onto say that people will move away from the labs to using the optigene.


13. Why do you think the share price is as low as it is and what in your opinion?
would be a fairer value up to date.
Even he has given up on trying to work out why its so low. They are working on building value to the company and at some point people will suddenly notice what omh is doing and that will be reflected in the share price in time. They are setting milestones and hitting them.



14. I think I heard someplace that omh had a meeting with some institutions to get
them interested in the company. If so how did it go and who were these companies.




15. Are there any plans to employ or reduce staff from within the company?

No plans to recruit or bin staff



16. Do you think this bird flue will benefit OMH in anyway on future sales and if so
how?

No, not unless there is a massive increase in infections. But some sales have been generated but are small.

23.Acqisistions.

They will be looking to buy into products from other companies that will fit in with omh and its products and will be make in their own factory in USA if opertunity arises.

Looks like Osmo are becoming the new distributor of a portable blood gas analysis device the AVOX 4000 replacing Abbott Labs.
http://www.osmetech.com/products/avox/avoximeter4000.htm A good way to build the portfolio with very little risk involved.
I wonder if this is a prelude to a buyout?
Guess this was the deal MW as chuntering about?

I think this could be replacing a deal they had with Abbot Labs to sell it.
Hmmmm now who do we know at Osmetech who has an Abbot connection....

http://www.avoxsystems.com/news.shtml
SAN ANTONIO, Texas, January 1, 2004 - Avox Systems Inc., announced today that it has terminated its sales promotion agreement with Abbott Laboratories. Under the agreement that ended on December 31, 2003, Abbott had sold Avox's unique portable co-oximeter, the AVOXimeter 4000, in the U.S. and Canada. In the U.S., Avox continues to sell the AVOXimeter 4000 factory direct. In addition, a private-label version of the AVOXimeter 4000, the GEMOPLTM*, continues to be available from Instrumentation Laboratory of Lexington, MA. The GEM OPLTM is currently sold worldwide. Avox Systems is now seeking foreign and domestic distributors to market the AVOXimeter 4000. Additional information is available at the company's website, http://www.avoxsystems.com.


Better get this thread updated!!!

Great News!

RNS Number:5558L
Osmetech PLC
27 April 2005





News Release



27th April 2005



Osmetech plc licences vial technology to Roche Diagnostics


Osmetech plc ("Osmetech") announced today that the AIM-listed international
diagnostics group has licensed its proprietary plastic tube technology to Roche
Diagnostics, Mannheim Germany. This plastic tube technology was acquired as part
of Osmetech's purchase of Molecular Sensing plc.

The worldwide non-exclusive license will enable Roche to develop, manufacture
and sell plastic consumable vials for use on its large installed base of
LightCycler(R) instruments as an alternative to existing glass vials.

The same technology has been incorporated into consumables to be supplied for
use with Osmetech's Opti GENE instrument scheduled to be exhibited at Medica
later this year. The Opti GENE is a fast and easy to use PCR based platform for
DNA and RNA analysis.

The terms of the license include an upfront payment to Osmetech plus royalties
based upon a percentage of the value of end user sales.

James White, CEO, Osmetech plc said, 'We are delighted that the acquisition of
Molecular Sensing has given us this opportunity to create additional revenue
before Opti GENE comes to market. Whilst those revenues will initially be
modest, we are pleased to be strengthening our relationship further with Roche
Diagnostics, one of the world's leading healthcare diagnostics companies.'



Ends



For further information:


James White, David Sandilands
Osmetech plc 020 7849 6027



Matthew Moth
madano partnership 020 7378 7033